A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Clinical trial NCT03729245 · TERMINATED
Trial details
- NCT number
- NCT03729245
- Sponsor
- Nektar Therapeutics
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-18
- Primary completion
- 2022-01-07
- Enrollment
- 623
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.